{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:08:37Z","timestamp":1693811317529},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T00:00:00Z","timestamp":1277164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s12029-010-9176-6","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T05:44:41Z","timestamp":1277099081000},"page":"68-72","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Metastatic Colorectal Cancer with Severe Liver Dysfunction Successfully Treated Using FOLFOX Therapy"],"prefix":"10.1007","volume":"42","author":[{"given":"Takaya","family":"Shimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoshi","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Mizoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tanida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Joh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,22]]},"reference":[{"issue":"9","key":"9176_CR1","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/S0959-8049(99)00150-1","volume":"35","author":"T Andre","year":"1999","unstructured":"Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer. 1999;35(9):1343\u20137. doi:10.1016\/S0959-8049(99)00150-1.","journal-title":"Eur J Cancer"},{"issue":"2","key":"9176_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229\u201337. doi:10.1200\/JCO.2004.05.113.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9176_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23\u201330. doi:10.1200\/JCO.2004.09.046.","journal-title":"J Clin Oncol"},{"issue":"9209","key":"9176_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041\u20137. doi:10.1016\/S0140-6736(00)02034-1.","journal-title":"Lancet"},{"issue":"12","key":"9176_CR5","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013\u20139. doi:10.1200\/JCO.2007.14.9930.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9176_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.2007.15.5390","volume":"26","author":"CS Fuchs","year":"2008","unstructured":"Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008;26(4):689\u201390. doi:10.1200\/JCO.2007.15.5390.","journal-title":"J Clin Oncol"},{"issue":"12","key":"9176_CR7","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539\u201344. doi:10.1200\/JCO.2006.09.6305.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9176_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/annonc\/mdf034","volume":"13","author":"CH Kohne","year":"2002","unstructured":"Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308\u201317. doi:10.1093\/annonc\/mdf034.","journal-title":"Ann Oncol"},{"issue":"2","key":"9176_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74\u2013108. doi:10.3322\/canjclin.55.2.74.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"9176_CR10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/annonc\/mdg302","volume":"14","author":"GF Fleming","year":"2003","unstructured":"Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, et al. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003;14(7):1142\u20137. doi:10.1093\/annonc\/mdg302.","journal-title":"Ann Oncol"},{"issue":"12","key":"9176_CR11","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1158\/1078-0432.CCR-06-2385","volume":"13","author":"TW Synold","year":"2007","unstructured":"Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007;13(12):3660\u20136. doi:10.1158\/1078-0432.CCR-06-2385.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"9176_CR12","first-page":"2182","volume":"7","author":"RH Mathijssen","year":"2001","unstructured":"Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7(8):2182\u201394.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"9176_CR13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/annonc\/mdg493","volume":"14","author":"AP Venook","year":"2003","unstructured":"Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003;14(12):1783\u201390. doi:10.1093\/annonc\/mdg493.","journal-title":"Ann Oncol"},{"issue":"3\u20134","key":"9176_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000081321","volume":"67","author":"MG Fakih","year":"2004","unstructured":"Fakih MG. 5-Fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology. 2004;67(3\u20134):222\u20134. doi:10.1159\/000081321.","journal-title":"Oncology"},{"issue":"3","key":"9176_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460\u20136.","journal-title":"Ann Oncol"},{"issue":"21","key":"9176_CR16","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","volume":"26","author":"HS Hochster","year":"2008","unstructured":"Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523\u20139. doi:10.1200\/JCO.2007.15.4138.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-010-9176-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-010-9176-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-010-9176-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-010-9176-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:08:46Z","timestamp":1628593726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-010-9176-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,22]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["9176"],"URL":"https:\/\/doi.org\/10.1007\/s12029-010-9176-6","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,22]]},"assertion":[{"value":"22 June 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}